Novel outcome measures for clinical trials in cystic fibrosis by Tiddens, H.A.W.M. (Harm) et al.
Pediatric Pulmonology 50:302–315 (2015)
Novel Outcome Measures for Clinical Trials
in Cystic Fibrosis
Harm A.W.M. Tiddens, MD, PhD,1* Michael Puderbach, MD,2 Jose G. Venegas, PhD,3
Felix Ratjen, MD, PhD, FRCPC,4 Scott H. Donaldson, MD,5 Stephanie D. Davis, MD,6
Steven M. Rowe, MD MSPH,7 Scott D. Sagel, MD, PhD,8 Mark Higgins, MBBS, BSc DCH, Med.,9 and
David A. Waltz, MD10
1Department of Pediatric Pulmonology and Allergology, Department of Radiology, Erasmus University Medical Center-Sophia Children’s Hospital,
Rotterdam, The Netherlands.
2Department for Diagnostic and Interventional Radiology, Hufeland Klinikum, Bad Langensalza, Germany.
3Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.
4Department of Pediatrics, Division of Respiratory Medicine, Hospital for Sick Children, University of Toronto, Toronto, Ontario.
5Department of Medicine, University of North Carolina, Chapel Hill, North Carolina.
6Department of Pediatrics, James Whitcomb Riley Hospital for Children, Indiana University School of Medicine, Indianapolis, Indiana.
7Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.
8Department of Pediatrics, Children’s Hospital Colorado, University of Colorado School of Medicine, Denver, Colorado.
9Vertex Pharmaceuticals Europe, Abingdon, UK.
10Vertex Pharmaceuticals, Boston, Massachusetts.
This is an open access article under the terms of the CreativeCommonsAttribution License, which permits use, distribution and reproduction in anymedium,
provided the original work is properly cited.
Conflicts of Interest: Harm Tiddens has received research grants from Novartis, Gilead, Roche and Chiesi for the “BV Kindergeneeskunde” of the Erasmus
Medical Center Sophia Children’s Hospital in the last 3 years. The BVKindergeneeskunde has also received honoraria for participation in expert panels for
Novartis, Gilead, Roche, Insmed, Pharmaxis, andVertex.Michael Puderbach has received support fromDFG,BMBF, andMukoviszidose e.V. grand, as well
as honoraria for participation in an expert panel for Novartis. Jose Venegas has received honoraria for lecturing for Bayer and for participating in an expert
panel for Novartis. He has also received research funding from Air Liquide. Felix Ratjen has received honoraria for serving as a consultant and lecturing for
Novartis. Scott Donaldson has received research grants from the NIH/NHLBI and CFF, and funding from research contracts with Vertex Pharmaceuticals,
MPEX Pharmaceuticals, Gilead Sciences, Novartis and Parion Sciences. Stephanie Davis has served on advisory boards for Novartis, Vertex
Pharmaceuticals and as a non-paid consultant for Eli Lilly. She has given lectures that were sponsored through educational grants from Vertex
Pharmaceuticals and Gilead. She has also received research grants from the NIH and CFF. Steven Rowe has received funding for the design and conduct of
clinical trials from Vertex Pharmaceuticals, PTC Therapeutics, N30 Pharmaceuticals and Novartis. His present work is supported by CFF (CLANCY05Y2)
and NIH (R01HL116213). Scott D. Sagel has received research grants from the NIH/NHLBI and CFF. Mark Higgins and David Waltz were employees of
Novartis at the time of this work and are currently employees of Vertex Pharmaceuticals, Inc.
Correspondence to: Harm A.W.M. Tiddens, MD, PhD, Professor of Pediatric Respiratory Medicine, Department of Pediatric Pulmonology and
Allergology, Department of Radiology, Erasmus University Medical Center-Sophia Children’s Hospital, P.O. box 2060, 3000 CB, Rotterdam, The
Netherlands. E-mail: h.tiddens@erasmusmc.nl
Received 2 May 2014; Revised 20 October 2014; Accepted 2 November 2014.
DOI 10.1002/ppul.23146
Published online 30 December 2014 in Wiley Online Library (wileyonlinelibrary.com).
 2014 The Authors. Pediatric Pulmonology published by Wiley Periodicals, Inc.
Summary. Cystic fibrosis (CF) is a common inherited condition caused by mutations in the
gene encoding the CF transmembrane regulator protein. With increased understanding of
the molecular mechanisms underlying CFand the development of new therapies there comes the
need to develop new outcome measures to assess the disease, its progression and response to
treatment. As there are limitations to the current endpoints accepted for regulatory purposes, a
workshop to discuss novel endpoints for clinical trials in CF was held in Anaheim, California in
November 2011. The pros and cons of novel outcomemeasureswith potential utility for evaluation
of novel treatments in CF were critically evaluated. The highlights of the 2011 workshop and
subsequent advances in technologies and techniques that could be used to inform the
development of clinical trial endpoints are summarized in this review. Pediatr Pulmonol. 2015;
50:302–315.  2014 The Authors. Pediatric Pulmonology published by Wiley Periodicals, Inc.
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CFTR activity.
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INTRODUCTION
Cystic fibrosis (CF) is caused by mutations in the gene
encoding the CF transmembrane conductance regulator
(CFTR) protein, an ion channel that transports chloride
ions across epithelial cell membranes. Therapeutic
progress has been realized over the last 20 years with
improved health, health-related quality of life (HRQoL)
and overall survival.1 These improvements may, in part,
be due to changes in therapeutic approach and patient
management. There has been a recent shift in the
treatment paradigm, with a reactive approach based on
responding to acute declines in respiratory health
giving way to a proactive approach of preventing
exacerbations and loss of lung function (Fig. 1),2 as
well as improving the functional and emotional well-
being of individuals.3
As life expectancy improves and decline in lung
function is reduced, the traditional endpoints for studies in
patients with CF, such as spirometry parameters, are
becoming less appropriate for assessing drug effects.4 In
addition, newborn screening has been widely adopted and
the introduction of disease-modifying therapies aimed at
correcting the function of the defective CFTR protein5
that could be started early in life seems imminent,
particularly following the recent approval of the first
CFTR potentiator.6 Hence there is a need for novel
endpoints that allow detection of clinical benefits starting
in young children and continuing into adulthood, which
are also acceptable to regulatory authorities. More
sensitive outcome measures may assist identification of
individuals who could benefit from a novel therapy,
reduce the sample size and shorten the duration of
intervention studies.4
Fig. 1. Stages of disease progression and pathologic changes that occur in the airways of
patients with CF as they age, along with possible treatment approaches. Reprinted with
permission of the American Thoracic Society. Copyright 2014 American Thoracic Society.
Ramsey BW. 2007. Use of lung imaging studies as outcome measures for development of new
therapies in cystic fibrosis. Proc Am Thorac Soc;4(4):359–63. Official Journal of the American
Thoracic Society.2
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A workshop to discuss novel endpoints for clinical
trials in CF was held in Anaheim, California, in
November 2011. The pros and cons of novel outcome
measures with potential to be used for evaluation of novel
treatments in CF were critically assessed. The aim of this
review is to summarize the highlights of this workshop,
together with more recent developments of clinical trial
endpoints for CF, in order to identify potential alternatives
that may be useful in future studies.
Pulmonary Function Testing
Parameters derived from spirometry, such as forced
expiratory volume in 1 sec (FEV1), still play an important
role as outcomemeasures in clinical trials. However, with
improved therapeutic options and earlier interventions,
FEV1 has become less useful as a tool for differentiating
between interventions, as differences in FEV1 are
reduced, so establishing statistical significance is more
difficult. Recently, end expiratory flows such as FEF25–75
and FEF75 have gained new interest as markers of early
lung disease. End expiratory flows show more variability
compared to FEV1, but they are substantially impaired in
early disease and have been shown to respond to therapy
in clinical studies.7–9
Unfortunately, standard spirometry cannot be routinely
used in children below the age of 6. For these young
children, preschool and infant pulmonary function tests
have been developed.10
Infant Pulmonary Function Testing
The raised volume rapid thoracoabdominal compres-
sion (RVRTC) technique (Table 1) is a reproducible,
repeatable and safe infant pulmonary function test (iPFT),
which allows the use of functional outcome parameters
for the diagnosis of airflow limitation and monitoring of
CF in sedated infants.11,12 Furthermore, standardized
guidelines for measurement and interpretation of results
obtained using RVRTC have been published and
commercial equipment is now available.12
Through the use of the RVRTC technique, investigators
have shown that lung function parameters are significant-
ly diminished in infants with CF, even in those as young as
3 months old.11,13,14 This finding suggests that RVRTC
parameters can identify early disease and may therefore
serve as useful clinical trial endpoints in infants with CF.
Early identification of disease is particularly relevant in
CF as therapeutic interventions aimed at preserving lung
function may be most effective when administered within
the first 6 months of life.15 In addition, RVRTC
parameters have been shown to be sensitive to inter-
ventions in infants with CF. A study has recently revealed
that forced expiratory flows and volumes improved
following antibiotic therapy for a pulmonary exacerbation
in a small subset of infants.16 In another recent clinical
trial, RVRTC parameters were evaluated as an explorato-
ry endpoint in a subset of patients randomized to either
7% hypertonic saline or isotonic saline for 1 year.17When
adjusted for baseline infant lung function, age, gender,
height, and weight, the mean change in FEV in 0.5 sec
(FEV0.5) over 1 year was significantly greater (by 38ml)
in the group treated with 7% hypertonic saline.17
However, it should be noted that acceptable measure-
ments were only obtained in 45 of 73 infants in this study,
and the clinical significance of a 38ml difference is not
known. Nevertheless, given these recent findings, the
commercial availability of equipment, and the promising
potential of iPFTs noted in the literature to date, it seems
worth pursuing the inclusion of functional parameters as
an outcome measure for clinical trials in infants.
However, disadvantages of the RVRTC technique that
form a hurdle for use as a primary endpoint must also be
considered. Infants must be sedated, equipment is
expensive, extensive training of personnel is required,
performing measurements is time consuming, and
normative data are limited.11,12,18 Despite these chal-
lenges, Davis et al. were able to conduct a prospective,
longitudinal, observational study with a commercial
device in 10 centers in the US.11 Personnel at each site
underwent rigorous training, and quality control and
independent reading of all data were performed by an
expert panel.11 In this study, key RVRTC parameters
were, on average, abnormal in infants with CF compared
with healthy historical control subjects.11 The authors
concluded that infant RVRTC parameters were not yet
ready to be adopted as primary efficacy endpoints for
multicenter clinical trials, particularly at inexperienced
sites and based on acceptability rates.11 However, the use
of iPFTs as a secondary endpoint should still be strongly
considered.
Multiple Breath Washout and the Lung Clearance Index
Parameters from the non-invasive, simple multiple
breath washout (MBW) tests include functional residual
capacity and lung clearance index (LCI) (Table 1). LCI is
determined by washout of an inert gas during tidal
breathing.19 As the washout takes longer to complete in
the presence of mucus retention or inflammation, LCI
increases with disease severity.19 LCI measures ventila-
tion inhomogeneity, which helps assess changes in small
airways that are not apparent while using spirometry.20
LCI has been shown to be superior to spirometry for the
detection of early lung disease in CF,20–23 while MBW
has been shown to be equivalent to RVRTC for detecting
early disease in infants.24
LCI has been demonstrated to correlate with structural
lung changes seen on computed tomography (CT) scans
in cross sectional studies, suggesting that these techniques
have similar sensitivity for the detection of CF lung
disease, and that using bothmethods in individual patients
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could elicit complementary information.21,25 A study in
pre-school children showed that an abnormal LCI at
preschool age could predict lung function abnormalities
at school age.4 In addition, a study including early
school age children demonstrated that LCI correlated
with quality of life, and that elevated LCI values
could predict pulmonary exacerbations (defined as
changes in respiratory status requiring intravenous anti-
biotics).26 Furthermore, LCI may also be a suitable
outcomemeasure to assess early intervention strategies in
pediatric patients, as studies among children with CF
using normal spirometry have shown LCI to be more
sensitive than FEV1 for detecting response to treatment
with dornase alfa, hypertonic saline, and ivacaftor
(in patients with a G551D-CFTR mutation and normal
FEV1).
27–29
One strength of LCI is that it has low variability, both
within and between tests,30,31 indicating that LCI is a
suitable endpoint for longitudinal studies.19 However,
limitations of LCI include that it may require sedation in
infants to increase its success rate. Furthermore, LCI is
affected by irregular breathing patterns, requirement for
expensive equipment such as mass spectrometers with
associated software to follow the concentration of the
inert gas, and the need for longer washouts as the disease
progresses.19 While sulfur hexafluoride-based mass
spectrometry measurements are considered to be the
gold standard,32 a number of devices have become
commercially available, but will need to undergo
thorough validation to assure accuracy of the measure-
ment. Sulfur hexafluoride gas mass spectrometry is not
commercially available,32 favoring nitrogen-based MBW
that only requires 100% oxygen which is readily available
in centers. The use of nitrogen-based MBW is increas-
ingly being favored over sulfur hexafluoride-based
methods and is more affordable than methods that require
mass spectroscopy. A device that determines nitrogen
concentration indirectly, by measuring both carbon
dioxide and oxygen concentrations, and using Dalton’s
law of partial pressures, has recently been validated.33 In
relation to its feasibility, the European CF Society clinical
trial network (ECFS-CTN) has selected a commercially
available nitrogen MBW system to be used in the
network. Over the last year many centers within the
network have acquired the system and are currently being
trained in its use. Similar efforts are ongoing in North
America and training centers have been established in
both London and Toronto.
Overall, LCI has potential as a clinical and research
outcome measure in young children with CF4 and in
single-dose, as well as multiple-dose studies.28 With
regard to the need for sedation, studies that will further
assess the suitability of LCI for clinical trials are currently
ongoing.29,34 A recent study demonstrating the utility of
LCI as an outcome measure in a multi-center trial.35
Imaging as an Outcome Measure
For the past 40 years, disease progression has been
evaluated through lung function tests and plain chest
radiographs. The implementation of multi-detector chest
CT scan technology has provided clinicians with a more
sensitive method for imaging CF lung damage.36 Various
types of imaging techniques are now used to determine the
presence and extent of lung disease in patients with CF,
including CT and chest magnetic resonance imaging
(MRI). In addition, scoring systems have been developed
to quantify and characterize the structural abnormalities
detected throughCTandMRI in patientswithCFat various
stages of the disease.37–39 These systems assess structural
changes such as bronchiectasis, trapped air, airway wall
thickening, mucus, and opacities. More recently, chest
MRI techniques have been developed allowing the
assessment of functional characteristics of the lung, as
well as the evaluation of lung morphology.40–42 Positron
emission tomography (PET) imaging with [18F]fluoro-
deoxyglucose ([18]FDG; FDG-PET) can also be used as a
non-invasive technique to quantify lung inflammation.43,44
CT Scans
Chest CT scans have been shown to bemore sensitive at
detecting disease severity than spirometry.25,36,45,46 In
particular, CT can be used to detect bronchiectasis and
trapped air, which reflects abnormal ventilation and
perfusion in infants.47 Studies have shown that there are
weak associations between the presence and extent of
structural lung damage and functional parameters.45,47,48
It has also been shown that infection, inflammation and
abnormal chest CT findings are already present in a
significant proportion of infants with CF at 3 months of
age46,49 and that these early structural changes are
progressive.46,50 These findings suggest that chest CT
could be used to detect the presence and extent of
structural lung disease, particularly as the majority of
infants with lung disease may be asymptomatic.46
Evaluation of the ability of chest CT to identify lung
abnormalities not detected by spirometry is an important
step in validating its use in the diagnosis and monitoring of
CF lung disease.51,52 Two studies showed that chest CT
scores are predictive of the respiratory tract exacerbation
rate, which is considered a key clinical efficacy outcome
measure in CF clinical studies,51,53 while another showed
that theCTscanbronchiectasis score (Brody-II system)was
strongly associated with the respiratory tract exacerbation
rate.51Moreover, time to first respiratory tract exacerbation
and hospitalization was significantly associated with
quartiles of bronchiectasis score as recorded by CT scan.51
Data from CT scans have also been correlated with
survival. In patients screened for lung transplantation,
individuals with a higher volume of infection/inflamma-
tion-like changes were shown to have a higher risk of
dying on the waiting list.54 In addition, there was a
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correlation between HRQoL scores and the presence of
structural changes on CT scans.55 Recent studies further
indicate that CT scans, and identification of bronchiecta-
sis in particular, can be useful in identifying children at
risk for worse pulmonary outcomes and could be used to
guide treatment decisions.36,56
The use of chest CTs in clinical trials has been shown to
be viable.55 However, as with spirometry, use of this
technique requires standardization, data transfer, and
centralized reading of images. A great advantage of chest
CT for clinical trials is that most CF centers have
scanners. However, as CT is based on ionizing radiation,
the radiation dose has to be minimized, especially in
young patients and when scans need to be repeated within
a relatively short study period.36,57 This can be achieved
by optimizing low-dose scanning protocols and current
CT techniques.58 Careful consideration should be given to
the balance between radiation exposure and potential
benefits.37 It is also necessary to define the optimal
balance between image modality, image quality, and
radiation exposure for each study protocol, at each
study site in multicenter clinical trials. In a cohort
study of children participating in the Wisconsin CF
Neonatal Screening Project, quantitative chest radiogra-
phy was shown to have excellent sensitivity for detecting
abnormal chest CT.59 In addition, efforts should be
directed at implementing strategies that have been shown
to reduce the radiation dose associated with chest CT
protocols.60–65 Using these strategies allows the radiation
dose of a chest CT to be reduced to within the range of a
routine chest radiograph.64,65 Regarding its feasibility,
over the last year 15 centers within the ECFS-CTN
participated in a CT standardization effort. Each center
was asked to characterize and optimize the CT scanners
using age-specific phantoms; personnel were also trained
in the use of a spirometry controlled chest CT protocol.
Similar efforts were made in 2 centers in North America
and in 9 centers in Australia. A training center has been
established in Erasmus MC Rotterdam.
Overall, bronchiectasis and trapped air detected by
chest CT are feasible and utilizable surrogate outcome
measures for clinical studies of novel treatments for
patients with CF (Table 1). Furthermore, due to the
increased sensitivity of CT scans compared with
spirometry, smaller sample sizes will be needed in
clinical studies employing CT scan endpoints.46 As CT is
a sensitive method of detection, it may be useful early in
life to detect signs of disease and act as a trigger for
initiating therapy before lung function measures, such as
FEV1, become noticeably impaired.
MRI
Pulmonary MRI has been introduced as a research and
diagnostic tool, primarily to overcome the limitations of
CT scans.41 However, pulmonary MRI also has some
limitations, such as the signal diminishing deeper into the
lung, respiratory and/or cardiac motion artifacts, and
magnetic field distortions due to lung parenchyma.41 Over
the last decade, technical advances have addressed these
limitations in functional and morphologic assessment of
various pulmonary diseases, including airway diseases.41
In particular, motion artifacts can be reduced by faster
imaging, so that controlled breathing is no longer
necessary for acceptable images.66
In patients with CF, MRI is useful for detecting
morphologic changes in airways and lung parenchyma, in
particular inflammation andmucus plugging,67 and can be
used in patients of almost all ages.42,68 In cross-sectional
studies, there is a strong correlation betweenMRI and CT
results in patients with CF.42 BothMRI and CTare able to
detect most largemorphologic changes in the CF lung, but
MRI is less sensitive for the detection of small airway
disease.57,69–71 New sequences are in development that
might further improve the resolution of MRI.
MRI has no radiation exposure, a clinically acceptable
scan time (15–30min), and is superior to CT for the
assessment of functional changes such as altered
pulmonary perfusion.57 Further, a reproducible morpho-
functional MR-scoring-system has been developed,
allowing CF lung disease over a broad severity range to
be monitored,40,68 although hyperperfusion is not taken
into account.
MRI is also sensitive to the effects of treatments
including antibiotics.72 The above mentioned features of
MRI may make it particularly suitable for monitoring the
course of functional pulmonary changes, such as
pulmonary perfusion in response to investigational
therapeutic interventions, and assessing other treatment
effects in clinical trials. A recent study in infants and pre-
school children with CF demonstrated that MRI was able
to detect abnormalities in lung structure and perfusion, as
well as response to treatment for exacerbations.68 These
findings confirm the potential of MRI for non-invasive
monitoring and as an outcome measure in interventional
trials for early CF lung disease.68
Overall, although MRI is a feasible and utilizable
surrogate outcome measure for clinical studies in patients
withCF (Table 1), further validation and standardization are
still needed.73 In addition,while there are no age limitations
to the use of MRI, imaging of children below the age of
6 years remains challenging. New methods are in develop-
ment, but are not yet in routine use.74 Experimental lung
imaging techniques that provide additional information on
ventilation beyond conventional MRI, such as hyper-
polarized noble gas (3He and129Xe) MRI75–77 and Fourier
decomposition MRI,78 are currently being evaluated.
PET Scanning
The utility of the FDG-PET scan is based on its unique
ability to image active infection and inflammation in the
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lungs.44,79 In particular, neutrophil (the predominant
inflammatory cell in the lungs of patients with CF)
activation can be detected using FDG-PET.44 Indeed,
FDG uptake in the damaged lung has been correlated with
uptake by neutrophils and may also be a biomarker of
eosinophilic inflammation.79,80 In patients with CF, a
decline in FEV1 has been associated with the rate of FDG
uptake.81 In contrast, adult patients with stable CF do not
show enhanced FDG uptake compared with control
patients, despite high sputum neutrophil levels.82
As the combination of CT and PET scans enables the
localization of inflammation to anatomical hotspots, the
use of hybrid FDG-PET/CT scanning was evaluated to
monitor lung inflammation and/or infection in patients
with CF.83 This study reported the presence of localized
areas of increased uptake of FDG that may represent
active focal infections or inflammatory processes in the
lungs.83 Moreover, in this study, the resolution of the
acute infection resulted in either a disappearance or great
reduction in the high-intensity areas of uptake.83 These
findings were recently confirmed in a FDG-PET/CT study
in 20 pediatric patients treated for a pulmonary
exacerbation.43 The above evidence, in conjunction
with clinical observation, has led to the suggestion that
FDG-PET/CT scanning may be more valuable than CT
for assessing responses to antibiotic treatment in CF
patients with acute lung infection.83 Furthermore, FDG-
PET/CT imaging could be enhanced by quantitative
measurements of regional ventilation and perfusion, to
increase sensitivity for detecting functional changes in the
lungs, as demonstrated previously for PET scanning.84–86
However, FDG-PET/CT exposes patients to relatively
high doses of ionizing radiation, which limits its repeated
use (Table 1). The combination of PET and MRI may
overcome this limitation as it could provide valuable
results with reduced radiation burden, which is of
particular importance in children where radiation expo-
sure must be minimized.
The advantages of FDG-PET and FDG-PET/CT scans
warrant further research. The development of improved
image analysis methods may help to validate this tool as
an endpoint for clinical trials.
Mucociliary Clearance
Although impaired mucociliary clearance (MCC) is a
hallmark of CF, current evidence suggests that MCC
varies significantly in children with CF lung disease and
normal pulmonary function, with MCC values reported
both within and below the normal range in this cohort.87
Furthermore, published studies on MCC as an outcome
measure have used different methods and yielded
inconsistent results.88–90 Robinson et al. demonstrated a
global reduction inMCC in CF patients regardless of their
lung function, including from the large airways.90 In
contrast, Donaldson et al. demonstrated that the 1 hr
mucus-clearance rate, which is dominated by large-
airway clearance, did not differ significantly between CF
patients and controls, whereas clearance in peripheral
lung regions and cumulative mucus clearance at 24 hr
(both reflective of the smaller airways) were significantly
reduced.88 Finally, another study showed that long-term
lung clearance measured over 21 days was not slower in
patients with CF than in healthy subjects.89 In this study,
greater clearance was reported in CF patients on days 1–7
and no difference in clearance was found between groups
from day 7 to day 21.89 Potential interpretations of the
absence of a difference in particle clearance after 7 days
include the absence of a small airway MCC problem, or
that clearance via mechanisms other than mucociliary
transport (e.g., macrophage-mediated clearance) domi-
nate during these very long time domains.89
MCC has several challenges that must be addressed
before use in clinical trials. Particle delivery and the
resulting pattern of lung deposition are critical determi-
nants of the observed clearance rate in MCC studies, and
therefore must be carefully controlled.91 Particle deposi-
tion depends on aerosol characteristics (average particle
size, distribution of size), the breathing pattern used
during inhalation (flow rate, tidal volume), and anatomi-
cal features of the airways (i.e., degree of obstruction and
lung size).91 Although total deposition tends to be
equivalent between patients with CF and controls, scans
have shown that deposition is patchy in patients with CF.
Particle clearance is also likely to be heterogeneous,89,91
potentially complicating the characterization and com-
parison of clearance rates. To minimize intra- and inter-
subject variability in particle deposition, aerosol delivery
to the bronchial airways must occur in a reproducible
manner.91 Variation in aerosol delivery methods likely
explains differences between prior studies, and failure to
control these variables can degrade the ability to
accurately characterize the response to therapeutic
interventions. A further limitation of MCC as an endpoint
is spontaneous cough and associated additional mucus
clearance that has been reported as a main adverse event
following inhaled medications.87 Finally, MCC is not
sensitive to all therapeutic agents; while sensitive to
agents that effectively change airway surface liquid
hydration, it was not altered by dornase alfa in previous
studies.92,93
Despite these limitations, recent findings suggest that
MCC has the potential to be used as an outcome measure
in CF clinical trials. Results from one study usingMCC to
assess the efficacy of hypertonic saline suggest that there
is an association between improvements inMCC and lung
function tests.88 In this study, MCC, FEV1, and forced
vital capacity significantly improved over treatment time
in patients receiving hypertonic saline, but not in those
who received the ineffective combination of amiloride
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and hypertonic saline.88 In the recent GOAL study, the
profound effect of restoring CFTR function on MCC,
using ivacaftor in patients with the G551D mutation, also
demonstrated the tight link between CFTR function and
MCC.94 In this multicenter study, MCC more than
doubled within 1 month of starting ivacaftor, and this
effect was maintained after 3 months of treatment. These
data suggest that MCC measurements may provide a
useful tool for the study of novel CFTR modulators in the
therapeutic pipeline.
At present, measurement of MCC is a promising, but
incompletely developed, biomarker for CF clinical
research (Table 1). A standard operating procedure has
recently been developed, which has facilitated the
conduct of multicenter studies.95 It should also be borne
inmind thatMCC is not sensitive to all therapeutic agents,
and therefore its application must be used selectively in
future clinical trials.
Biomarkers as Outcome Measures
Sputum Biomarkers
Sputum is easily obtainable and a rich source of
biomarkers of inflammation and infection in patients with
CF.96–98 As airway inflammation plays a central role in
CF lung disease, sputum biomarkers of inflammation that
can be used to monitor disease activity or evaluate
response to therapy would be valuable. Biomarkers may
also provide further insight into the pathophysiology of
CF lung disease.
Findings from small single-center studies are limited,
but support an association between sputum biomarkers
and disease status in CF, as determined by pulmonary
function tests, chest radiograph scores, HRQoLmeasures,
and illness severity scores (e.g., Shwachman–Kulczycki
score).97 Significant correlations between FEV1 and
sputum inflammatory measures, including neutrophil
counts, interleukin (IL)-8, and neutrophil elastase, have
also been demonstrated in a diverse CF population
across multiple centers participating in four CF clinical
trials.99
Several studies have demonstrated good reproducibili-
ty of cell counts and inflammatory mediators in induced
sputum.97,100–102 Emerging longitudinal analyses of
sputum biomarkers provide variability estimates over
time, allowing investigators to derive sample size
calculations for interventional trials.103,104
Reductions in sputum biomarkers following therapeu-
tic intervention have been demonstrated in a number of
clinical studies.105–107 Following intravenous antibiotic
therapy in patients with CF, reductions in neutrophil
counts, IL-8 concentration and neutrophil elastase
activity were associated with improvements in FEV1.
106
Importantly, sputum induction was relatively well
tolerated in CF patients, even during acute pulmonary
exacerbations.106 In the initial US azithromycin trial,
therewere modest differences in sputum elastase between
the placebo and treated groups at the end of treatment in
favor of the azithromycin group, suggesting that
azithromycin may exert an anti-inflammatory effect by
preventing a worsening of protease-mediated inflamma-
tion over time.107 Two other studies, one investigating the
anti-inflammatory effects of ibuprofen,108 the other
examining the CFTR potentiator ivacaftor in G551D
subjects,94 did not show significant changes in sputum
biomarkers of airway inflammation. While these studies
raise concerns about the utility of sputum biomarkers, the
lack of significant changes could also be attributed to
the relatively short treatment periods and the need for
more prolonged therapies before substantially impacting
airway inflammation. Other potential sputum biomarkers
that might be relevant to CF clinical trials include
biomarkers of structural injury andmatrix degradation;109
physical properties, including wet and dry weight, surface
tension and impedance; rheology (viscosity, elasticity),
andmicroparticles;110 as well as biochemical constituents
besides inflammatory mediators (mucins, fibrin, DNA).
Overall, sputum assessments provide a non-invasive
endpoint for assessing novel therapies for CF, especially in
patients over 10 years of age. Ongoing investigations into
the variability and reproducibility of this technique are a
practical step beforewidespread application in clinical trial
methodology. In addition, longitudinal analyses are
essential for the validation of biomarkers of inflammation,
as correlates of disease severity and progression. Data are
now emerging from ongoing investigations evaluating the
ability of sputum biomarkers to predict key clinical events
in CF, including lung function decline,104,111 pulmonary
exacerbations,103,105 development of bronchiectasis47 and
even survival.103 Taken together, these data provide strong
support for the use of sputum biomarkers of airway
inflammation as tools to monitor disease activity and as
outcome measures in CF clinical trials.
Blood-Based Biomarkers
Serum and plasma biomarkers have the potential to
provide a relatively non-invasive means of evaluating
pulmonary inflammation and infection in patients with
CF. Several circulating biomarkers have been investigat-
ed, including C-reactive protein, serum amyloid A,
calprotectin, neutrophil elastase antiprotease complexes,
plasma sCD14, a protein complex containing alfa-1
antitrypsin and CD16b (AAT:CD16b), and cytokines
including IL-6 and IL-8.112–115 A recent systematic
review summarized the results of studies that have used
blood-based biomarkers to monitor response to treatment
during pulmonary exacerbations.116 In a clinical trial in
CF patients 6–18 years of age uninfected with Pseudo-
monas aeruginosa, azithromycin significantly reduced
circulating neutrophil counts and systemic markers of
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inflammation including C-reactive protein, serum amy-
loid A, and calprotectin.117 Reduction in these inflamma-
tory markers correlated with improvements in lung
function and weight gain, providing indirect evidence
that these changes were associated with clinically
meaningful outcomes. This was the first study to
demonstrate the utility of a panel of systemic inflamma-
tory markers in a CF interventional trial and these data
provide evidence that systemic biomarkers have added
value and should be included in future CF clinical trials.
Exhaled Breath Condensate
Exhaled breath condensate (EBC) may provide a
potential source of biomarkers that could be useful in a
variety of diseases, including CF.118 Several potential
EBC biomarkers have been investigated in CF, including
EBC pH, fractional exhaled nitric oxide, leukotriene-B4,
8-isoprostane, hydrogen peroxide, interferon-g, IL-10,
IL-4, tumor necrosis factor, purines and glucose.118 At
present there is insufficient evidence to support the use of
any of these biomarkers as outcome measures in clinical
studies.
Assessment of CFTR Activity
Nasal Potential Difference
It is well established that CF is caused by mutations in
the CFTR gene, resulting in disruption of chloride and
bicarbonate transport across epithelial cell membranes.119
These abnormalities can be evaluated by measuring the
transepithelial potential difference (PD) across the nasal
epithelium. The degree of CFTR dysfunction, as
measured by nasal PD, correlates with the number and
severity of CFTR gene mutations.120 Measurement of
nasal PD has therefore proved useful in clinical studies of
novel CFTR therapeutic agents121–124 and is used in
clinical practice as one of the diagnostic criteria for
CF.125–127 However, there are several different methods
for measuring nasal PD, as well as important consider-
ations with respect to its use in clinical trials, such as the
requirement for well-trained and dedicated personnel to
provide accurate assay results.128 Commercially-avail-
able equipment, which has made this measurement easier
to perform, is now in use.129 The agar nasal catheter has
shown greater reliability than the perfusion nasal catheter
for measurement of nasal PD,130 and its sensitivity and
specificity are generally understood.131,132 The tool has
been particularly useful for evaluating the response,
including the effect of different doses of the CFTR
potentiator ivacaftor, in G551D CF patients.121
PDmeasurements can also be made in the lower airway
via bronchoscopy,133,134 thus permitting direct assess-
ment of the airways. This could be particularly important
for evaluating the effect of inhaled drugs or gene therapy
in which only pulmonary delivery is expected. A study
has shown that invasive bronchoscopic methods can be
utilized safely and reliably in children as young as 1 year
of age, albeit under anesthesia.133 Therefore, this measure
could be a useful functional endpoint assay for studies of
either CFTR gene transfer or for future trials evaluating
inhaled therapeutics.
Intestinal Current Measurement (ICM)
Intestinal current measurement (ICM) was introduced
about two decades ago as an ex vivo diagnostic method
for CF and has been the subject of renewed interest.135–140
The technique can distinguish pancreatic-sufficient
individuals, indicating its utility in quantifying patient
phenotype.141 ICM has some advantages over nasal and
lower airway PD techniques, including easy access to
intestinal tissue in all age groups and minimal tissue
damage or remodeling triggered by bacterial or viral
infections.136 Moreover, ICM allows novel CFTR thera-
pies to be studied in native human epithelium ex vivo
without increasing risk to the patient and is able to detect
low levels of functionally active CFTR.136 The potential
use of ICM in clinical trials is being evaluated, and has
been combined with protein detection by Western
blotting.136 In addition, standardized guidelines for this
technique are now available, following collaboration
between the European CF Society Diagnostic Network
Working Group, the European CF Society Clinical Trials
Network and the CF Foundation Therapeutics Develop-
ment Network.142
Sweat Test
Determination of sweat electrolytes has been per-
formed in clinical laboratories for over 40 years and
remains the gold standard diagnostic test for CF.143 The
measure provides a sensitive indicator of CFTR activity,
and correlates well with the CF phenotype.120 Sweat
chloridemeasurements are feasible in multicenter clinical
trials,5,121,122,143 and use of the macroduct collection
system allows analysis in a central laboratory, facilitating
standardized methodology among centers. Furthermore,
the procedure does not place a significant burden on
patients and is rarely associated with complications.143
Several lines of evidence suggest that sweat chloride is a
robust outcome measure in clinical trials evaluating
agents directed at restoring CFTR function.5,121,122 As
sweat chloride levels change significantly with small
changes in CFTR activity, as seen in genotype–phenotype
correlations,120 their determination allows the evaluation
of the effect of CFTR modulators with relatively low
activity,122 providing a reasonable assay for dose-
response relationships. However, change in sweat
chloride has not proven to be predictive of lung function
response on an individual basis in studies involving a
CFTR potentiator.144 Recently, sweat rate and sweat
conductivity have been determined in conjunction with
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sweat chloride levels, to assess the secretory function of
the sweat gland.145,146 These techniques may be
particularly well suited to detecting altered glandular
activity, although this needs to be demonstrated in
prospective studies.
In conclusion, application of ion channel measure-
ments in clinical trials appears feasible given its
established use, favorable safety and acceptability profile
and validity (Table 1). Widespread use in recent years has
improved understanding of its sensitivity, specificity, and
reproducibility.121,122,145,147,148 However, the need for
well-trained personnel and use of accepted standard
operating procedures should be employedwhen including
sweat chloride as an outcome measure in clinical trials. In
addition, concerns regarding whether pharmacodynamic
activity in the absorptive epithelium of the sweat gland
correlates with activity in the secretory epithelia of the
airway and other organs still need to be addressed.149 This
could be achieved by characterizing CFTR, and its
response to novel therapies, in different tissues. Other
questions includewhether tissue (i.e., skin) penetration or
differences in the absorptive function of CFTR following
pharmacologic rescue of F508del may impair its ability to
detect the efficacy of multi-agent therapy.
CONCLUSION
Spirometry is the standard clinical trial endpoint in
older children and adults with CF. However, it is now
well recognized that, over time, decline in FEV1 has
become relatively small, thus making it an insufficiently
sensitive marker of CF to serve as a primary endpoint
in clinical studies. There is consequently an urgent
need for alternative sensitive and accurate surrogate
outcome measures that detect early lung disease and
track disease progression through early childhood into
adulthood.4
Ideally endpoints must be accurate, reproducible,
sensitive, and reflect patient function and survival. They
should also predict the efficacy of therapy,99,145,147 as well
as being feasible for use in clinical studies with small
patient numbers, non-invasive and inexpensive. The most
promising and feasible new sensitive outcome measures
that can be used in today’s clinical trials to measure
severity of CF lung disease in (young) children and adults,
are the LCI and the bronchiectasis scores derived from
chest CT. Tests to measure CFTR activity, such as the
sweat test, are of key importance to establish the effect of
CFTR modifiers on CFTR function.
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